Eli Lilly and Company has completed a record $9 billion bond issuance to fund an aggressive acquisition strategy, highlighted by the recent purchases of Centessa Pharmaceuticals and Kelonia Therapeutics. This financial maneuver follows a remarkable 56% year-on-year revenue growth, driven largely by soaring demand for its GLP-1 weight-loss drugs, Mounjaro and Zepbound. Following this news, Eli Lilly's stock rose by 6%, reflecting strong investor confidence and an upgraded credit rating from S&P Global Ratings, positioning the company for further expansion in the pharmaceutical market.
“Major technology companies · investing · artificial intelligence infrastructure · $650 billion annually”
“Eli Lilly · collaborated with · Insilico Medicine · $2.75 billion”
“Eli Lilly · delivered year-on-year revenue growth · of 55.5% · beating analysts’ expectations by 13.7%”
“Eli Lilly stock · recovered · Monday · after a patient taking its new weight-loss pill, Foundayo, experienced liver failure”
“Eli Lilly stock · toppled · Monday · after a patient taking its new weight-loss pill, Foundayo, experienced liver failure”
“Eli Lilly stock · dipped · Monday · true”
“Eli Lilly · holds · 60% market share · in U.S. GLP-1 market”
“Foundayo · is a growth opportunity for · Lilly”
“Eli Lilly · continues to advance · other weight loss candidates · through the pipeline”
“major technology companies · investing · AI infrastructure · $650 billion annually”
“Eli Lilly · collaborated with · Insilico Medicine · $2.75 billion”
“major technology companies · investing · AI infrastructure · $650 billion annually”
.jpg&width=160)